ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Atypical Hemolytic Uremic Syndrome Drug Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-37U9323
Home | Market Reports | Health| Health Conditions
Global Atypical Hemolytic Uremic Syndrome Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Global Atypical Hemolytic Uremic Syndrome Drug Market Research Report 2025

Code: QYRE-Auto-37U9323
Report
September 2025
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Amgen Inc
ChemoCentryx Inc
greenovation Biotech GmbH
Kedrion SpA
Omeros Corp

Atypical Hemolytic Uremic Syndrome Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Atypical Hemolytic Uremic Syndrome Drug Market

Atypical Hemolytic Uremic Syndrome Drug Market

The global market for Atypical Hemolytic Uremic Syndrome Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Atypical Hemolytic Uremic Syndrome Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Atypical Hemolytic Uremic Syndrome Drug.
The Atypical Hemolytic Uremic Syndrome Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Atypical Hemolytic Uremic Syndrome Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Atypical Hemolytic Uremic Syndrome Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Atypical Hemolytic Uremic Syndrome Drug Market Report

Report Metric Details
Report Name Atypical Hemolytic Uremic Syndrome Drug Market
CAGR 5%
Segment by Type
  • ALN-CC5
  • CCX-168
  • ET-006
  • ETR-001
  • Mubodina
  • OMS-72
  • Others
Segment by Application
  • Clinic
  • Hospital
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Achillion Pharmaceuticals Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Amgen Inc, ChemoCentryx Inc, greenovation Biotech GmbH, Kedrion SpA, Omeros Corp
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Atypical Hemolytic Uremic Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Atypical Hemolytic Uremic Syndrome Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Atypical Hemolytic Uremic Syndrome Drug Market report?

Ans: The main players in the Atypical Hemolytic Uremic Syndrome Drug Market are Achillion Pharmaceuticals Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Amgen Inc, ChemoCentryx Inc, greenovation Biotech GmbH, Kedrion SpA, Omeros Corp

What are the Application segmentation covered in the Atypical Hemolytic Uremic Syndrome Drug Market report?

Ans: The Applications covered in the Atypical Hemolytic Uremic Syndrome Drug Market report are Clinic, Hospital, Others

What are the Type segmentation covered in the Atypical Hemolytic Uremic Syndrome Drug Market report?

Ans: The Types covered in the Atypical Hemolytic Uremic Syndrome Drug Market report are ALN-CC5, CCX-168, ET-006, ETR-001, Mubodina, OMS-72, Others

Recommended Reports

Kidney Disease Drugs

Blood Disorders Drugs

Autoimmune Disorders

1 Atypical Hemolytic Uremic Syndrome Drug Market Overview
1.1 Product Definition
1.2 Atypical Hemolytic Uremic Syndrome Drug by Type
1.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 ALN-CC5
1.2.3 CCX-168
1.2.4 ET-006
1.2.5 ETR-001
1.2.6 Mubodina
1.2.7 OMS-72
1.2.8 Others
1.3 Atypical Hemolytic Uremic Syndrome Drug by Application
1.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Value by Application (2024 VS 2031)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Atypical Hemolytic Uremic Syndrome Drug Market Size Estimates and Forecasts
1.4.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue 2020-2031
1.4.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales 2020-2031
1.4.3 Global Atypical Hemolytic Uremic Syndrome Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Atypical Hemolytic Uremic Syndrome Drug Market Competition by Manufacturers
2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Atypical Hemolytic Uremic Syndrome Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Atypical Hemolytic Uremic Syndrome Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Product Type & Application
2.7 Global Key Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Date of Enter into This Industry
2.8 Global Atypical Hemolytic Uremic Syndrome Drug Market Competitive Situation and Trends
2.8.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Atypical Hemolytic Uremic Syndrome Drug Players Market Share by Revenue
2.8.3 Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Atypical Hemolytic Uremic Syndrome Drug Market Scenario by Region
3.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2020-2031
3.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2020-2025
3.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2026-2031
3.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2020-2031
3.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2020-2025
3.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2026-2031
3.4 North America Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
3.4.1 North America Atypical Hemolytic Uremic Syndrome Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2020-2031)
3.4.3 North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
3.5.1 Europe Atypical Hemolytic Uremic Syndrome Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2020-2031)
3.5.3 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
3.7.1 Latin America Atypical Hemolytic Uremic Syndrome Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2020-2031)
3.7.3 Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2020-2031)
4.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2020-2025)
4.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2026-2031)
4.1.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2020-2031)
4.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2020-2031)
4.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2020-2025)
4.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2026-2031)
4.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2020-2031)
4.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2020-2031)
5.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2020-2025)
5.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2026-2031)
5.1.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2020-2031)
5.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2020-2031)
5.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2020-2025)
5.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2026-2031)
5.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2020-2031)
5.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Achillion Pharmaceuticals Inc
6.1.1 Achillion Pharmaceuticals Inc Company Information
6.1.2 Achillion Pharmaceuticals Inc Description and Business Overview
6.1.3 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
6.1.5 Achillion Pharmaceuticals Inc Recent Developments/Updates
6.2 Akari Therapeutics Plc
6.2.1 Akari Therapeutics Plc Company Information
6.2.2 Akari Therapeutics Plc Description and Business Overview
6.2.3 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
6.2.5 Akari Therapeutics Plc Recent Developments/Updates
6.3 Alexion Pharmaceuticals Inc
6.3.1 Alexion Pharmaceuticals Inc Company Information
6.3.2 Alexion Pharmaceuticals Inc Description and Business Overview
6.3.3 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
6.3.5 Alexion Pharmaceuticals Inc Recent Developments/Updates
6.4 Amgen Inc
6.4.1 Amgen Inc Company Information
6.4.2 Amgen Inc Description and Business Overview
6.4.3 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
6.4.5 Amgen Inc Recent Developments/Updates
6.5 ChemoCentryx Inc
6.5.1 ChemoCentryx Inc Company Information
6.5.2 ChemoCentryx Inc Description and Business Overview
6.5.3 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
6.5.5 ChemoCentryx Inc Recent Developments/Updates
6.6 greenovation Biotech GmbH
6.6.1 greenovation Biotech GmbH Company Information
6.6.2 greenovation Biotech GmbH Description and Business Overview
6.6.3 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
6.6.5 greenovation Biotech GmbH Recent Developments/Updates
6.7 Kedrion SpA
6.7.1 Kedrion SpA Company Information
6.7.2 Kedrion SpA Description and Business Overview
6.7.3 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
6.7.5 Kedrion SpA Recent Developments/Updates
6.8 Omeros Corp
6.8.1 Omeros Corp Company Information
6.8.2 Omeros Corp Description and Business Overview
6.8.3 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
6.8.5 Omeros Corp Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Atypical Hemolytic Uremic Syndrome Drug Industry Chain Analysis
7.2 Atypical Hemolytic Uremic Syndrome Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Atypical Hemolytic Uremic Syndrome Drug Production Mode & Process Analysis
7.4 Atypical Hemolytic Uremic Syndrome Drug Sales and Marketing
7.4.1 Atypical Hemolytic Uremic Syndrome Drug Sales Channels
7.4.2 Atypical Hemolytic Uremic Syndrome Drug Distributors
7.5 Atypical Hemolytic Uremic Syndrome Drug Customer Analysis
8 Atypical Hemolytic Uremic Syndrome Drug Market Dynamics
8.1 Atypical Hemolytic Uremic Syndrome Drug Industry Trends
8.2 Atypical Hemolytic Uremic Syndrome Drug Market Drivers
8.3 Atypical Hemolytic Uremic Syndrome Drug Market Challenges
8.4 Atypical Hemolytic Uremic Syndrome Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Amgen Inc
ChemoCentryx Inc
greenovation Biotech GmbH
Kedrion SpA
Omeros Corp
List of Tables
 Table 1. Global Atypical Hemolytic Uremic Syndrome Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Atypical Hemolytic Uremic Syndrome Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Atypical Hemolytic Uremic Syndrome Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Atypical Hemolytic Uremic Syndrome Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Atypical Hemolytic Uremic Syndrome Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Atypical Hemolytic Uremic Syndrome Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Atypical Hemolytic Uremic Syndrome Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Atypical Hemolytic Uremic Syndrome Drug Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Atypical Hemolytic Uremic Syndrome Drug Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Atypical Hemolytic Uremic Syndrome Drug Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Atypical Hemolytic Uremic Syndrome Drug Price (USD/Pcs) by Application (2026-2031)
 Table 70. Achillion Pharmaceuticals Inc Company Information
 Table 71. Achillion Pharmaceuticals Inc Description and Business Overview
 Table 72. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product
 Table 74. Achillion Pharmaceuticals Inc Recent Developments/Updates
 Table 75. Akari Therapeutics Plc Company Information
 Table 76. Akari Therapeutics Plc Description and Business Overview
 Table 77. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product
 Table 79. Akari Therapeutics Plc Recent Developments/Updates
 Table 80. Alexion Pharmaceuticals Inc Company Information
 Table 81. Alexion Pharmaceuticals Inc Description and Business Overview
 Table 82. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product
 Table 84. Alexion Pharmaceuticals Inc Recent Developments/Updates
 Table 85. Amgen Inc Company Information
 Table 86. Amgen Inc Description and Business Overview
 Table 87. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product
 Table 89. Amgen Inc Recent Developments/Updates
 Table 90. ChemoCentryx Inc Company Information
 Table 91. ChemoCentryx Inc Description and Business Overview
 Table 92. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product
 Table 94. ChemoCentryx Inc Recent Developments/Updates
 Table 95. greenovation Biotech GmbH Company Information
 Table 96. greenovation Biotech GmbH Description and Business Overview
 Table 97. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product
 Table 99. greenovation Biotech GmbH Recent Developments/Updates
 Table 100. Kedrion SpA Company Information
 Table 101. Kedrion SpA Description and Business Overview
 Table 102. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product
 Table 104. Kedrion SpA Recent Developments/Updates
 Table 105. Omeros Corp Company Information
 Table 106. Omeros Corp Description and Business Overview
 Table 107. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 108. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product
 Table 109. Omeros Corp Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Atypical Hemolytic Uremic Syndrome Drug Distributors List
 Table 113. Atypical Hemolytic Uremic Syndrome Drug Customers List
 Table 114. Atypical Hemolytic Uremic Syndrome Drug Market Trends
 Table 115. Atypical Hemolytic Uremic Syndrome Drug Market Drivers
 Table 116. Atypical Hemolytic Uremic Syndrome Drug Market Challenges
 Table 117. Atypical Hemolytic Uremic Syndrome Drug Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Atypical Hemolytic Uremic Syndrome Drug
 Figure 2. Global Atypical Hemolytic Uremic Syndrome Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Type: 2024 & 2031
 Figure 4. ALN-CC5 Product Picture
 Figure 5. CCX-168 Product Picture
 Figure 6. ET-006 Product Picture
 Figure 7. ETR-001 Product Picture
 Figure 8. Mubodina Product Picture
 Figure 9. OMS-72 Product Picture
 Figure 10. Others Product Picture
 Figure 11. Global Atypical Hemolytic Uremic Syndrome Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 12. Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Application: 2024 & 2031
 Figure 13. Clinic
 Figure 14. Hospital
 Figure 15. Others
 Figure 16. Global Atypical Hemolytic Uremic Syndrome Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Atypical Hemolytic Uremic Syndrome Drug Market Size (2020-2031) & (US$ Million)
 Figure 18. Global Atypical Hemolytic Uremic Syndrome Drug Sales (2020-2031) & (K Pcs)
 Figure 19. Global Atypical Hemolytic Uremic Syndrome Drug Average Price (USD/Pcs) & (2020-2031)
 Figure 20. Atypical Hemolytic Uremic Syndrome Drug Report Years Considered
 Figure 21. Atypical Hemolytic Uremic Syndrome Drug Sales Share by Manufacturers in 2024
 Figure 22. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Manufacturers in 2024
 Figure 23. Global 5 and 10 Largest Atypical Hemolytic Uremic Syndrome Drug Players: Market Share by Revenue in Atypical Hemolytic Uremic Syndrome Drug in 2024
 Figure 24. Atypical Hemolytic Uremic Syndrome Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 25. Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 26. North America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2020-2031)
 Figure 27. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2020-2031)
 Figure 28. U.S. Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Canada Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2020-2031)
 Figure 31. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2020-2031)
 Figure 32. Germany Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. France Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. U.K. Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Italy Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Russia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2020-2031)
 Figure 38. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2020-2031)
 Figure 39. China Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Japan Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. South Korea Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. India Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Australia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Taiwan Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Indonesia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Thailand Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Malaysia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Philippines Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. UAE Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of Atypical Hemolytic Uremic Syndrome Drug by Type (2020-2031)
 Figure 60. Global Revenue Market Share of Atypical Hemolytic Uremic Syndrome Drug by Type (2020-2031)
 Figure 61. Global Atypical Hemolytic Uremic Syndrome Drug Price (USD/Pcs) by Type (2020-2031)
 Figure 62. Global Sales Market Share of Atypical Hemolytic Uremic Syndrome Drug by Application (2020-2031)
 Figure 63. Global Revenue Market Share of Atypical Hemolytic Uremic Syndrome Drug by Application (2020-2031)
 Figure 64. Global Atypical Hemolytic Uremic Syndrome Drug Price (USD/Pcs) by Application (2020-2031)
 Figure 65. Atypical Hemolytic Uremic Syndrome Drug Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Research Report 2025
Drug Induced Immune Hemolytic Anemia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Kidney Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Renal Disease Treatment Market Research Report 2024
Global Chronic Kidney Disease Drugs Market Research Report 2025
Global Hemophilia A Drug Market Research Report 2024
Global Renal Anemia Therapeutics Market Research Report 2025
Global Hemoglobinopathies Drugs Market Research Report 2024
Rare Kidney Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Urinary Tract Infection Therapeutics Market Research Report 2025
Global Drug induced Nephrotoxicity Treatment Market Research Report 2025
Global Complement Drug for Kidney Disease Market Research Report 2024
Global Continuous Renal Replacement Therapy Market Research Report 2024
Global Kidney Cancer Diagnosis Market Research Report 2025
Kidney Fibrosis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Acute Kidney Injury Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Haemophilia Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematological Malignancies Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Urinary System Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Aquaculture Bacterial Diagnosis Market Research Report 2025

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Chronic Pain Medical Devices Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0I20198
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Disposable Insulin Pen Needle Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33W11115
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32E19705
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions